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Tiivistelmä 
Taustat ja tavoitteet: Hiilihappoanhydraasi VI, CA VI, on hiilihappoanhydraaseihin 
kuuluva erittyvä isoentsyymi, jonka tiedetään ihmisellä erittyvän sylkirauhasen 
serooseista rauhassoluista sylkeen sekä rinnan maitorauhasen soluista äidinmaitoon. 
CA VI:n kokoa on tutkittu SDS-PAGE-elektroforeesilla sekä Western blottauksella, 
mutta ei nestekromatografian ja valonsironnan keinoin. Aiemmin ei ole myöskään 
tutkittu mahdollisia eroja syljen ja maidon CA VI:n aminohappoketjujen sokeriosissa, 
eli glykosylaatioissa.  Tämän tutkimuksen tavoitteena oli määrittää maidon ja syljen 
hiilihappoanhydraasi VI:n molekyylipaino ja koko fysiologisessa puskurissa. Lisäksi 
haluttiin selvittää maidon ja syljen hiilihappoanhydraasi VI:n aminohappoketjujen 
mahdollisia sokeriosien eroja sekä tutkia CA VI:n sulamislämpöä.  
Metodit: CA VI-isoentsyymien molekyylipainoa ja kokoa tutkittiin niin SDS-PAGE-
elektroforeesilla kuin nestekromatografialla, sekä staattisella ja dynaamisella 
valonsironnalla. Sulamislämpö syljen CA VI:lle määritettiin 
differentiaaliskannauskalorimetrialla. Massaspektrometrisia analyyseja ei pystytty 
täydellisesti suorittamaan laitevian vuoksi.  
Tulokset: Staattisen valonsironnan ja standardoidun molekyylipainomäärityksen 
perusteella maidon CA VI:n molekyylimassa oli 203,815 kD ja syljen CA VI:n oli 
204,509 kD. Syljen CA VI:n halkaisijan mitattiin olevan 20,3 ± 1,3 nm ja 
sulamislämmön olevan 50-55°C asteen välillä.  
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Johtopäätökset: Voidaan todeta sekä maidon että syljen hiilihappoanhydraasi VI ovat 
fysiologisessa puskurissa oligomeerisiä, pentameerisen muodon ollessa 
todennäköisin. CA VI:n oligomeerista muotoa ei ole raportortoitu ennen. Sen 
olemassaolo mahdollistaa pentameerin mielekkäät jatkotutkimukset toiminnallisuuden 
selvittämiseksi.  
Abstract  
Background and aims of study: Carbonic anhydrase VI, CA VI, belongs to carbonic 
anhydrase isoenzymes that is known to secrete from serous acinar cells in the salivary 
glands and mammary gland to saliva and milk, respectively. The molecular weight of 
CA VI has been assessed with SDS-PAGE-electrophoresis as well as with Western 
blotting, yet not with liquid chromatography and light scattering. Also, the differences 
in the amino acid chains of milk and salivary CA VI are not thoroughly assessed. The 
aim of this study was to determine the molecular weight and particle size of milk and 
salivary CA VI in the physiological buffer. In addition, potential glycosylation 
differences and the melting temperature of CA VI were desired to study. 
Methods: The molecular weight and particle size of CA VI isoenzymes were analyzed 
with SDS-PAGE, size-exclusion chromatography and light scattering, both static and 
dynamic, respectively. The melting temperature for salivary CA VI was determined 
with differential scanning calorimetry. The mass spectrometric analyses were not 
completed due to the malfunction of the apparatus. 
Results: Based on SLS and standardized molecular weight determination, milk CA VI 
was shown to have the molecular weight of 203,815 kD and salivary CA VI was 
measured to be 204,509 kD. The hydrodynamic diameter for salivary CA VI was 
determined to be 20,3 ± 1,3 nm and the melting point was shown to be in the range 
of 50-55°C.  
Conclusions: 
It can be concluded that both milk and salivary CA VI exist as oligomeric proteins in 
the physiological buffer. The pentameric state is probably the most prevalent form of 
assembly, which has not been reported earlier for any human CA isoenzyme. The 
existence of such a unique form opens new avenues for elucidating the prevalence 
and functional role of oligomerization in CA VI.      
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CA Carbonic anhydrase 
SN2 Reaction mechanism of nucleophilic substitution 
CARP Carbonic anhydrase-related protein 
gustin Alternative name for carbonic anhydrase VI 
cAMP Cyclic adenosine monophosphate 
PDEase Phosphodiesterase enzyme 
DMFT-index Decayed, missing or filled teeth index 
PROP Propylithiouracil, study item 
pSS Primary Sjögren’s syndrome 
PTX Pentraxin 
GalNAc-4-SO4 Galactose-N-acetylgalactosamine-4-SO4 receptor 
RT-PCR Reverse transcriptase PCR 
ELISA Enzyme-linked immunosorbent assay 
q-PCR Quantitative PCR 
HPLC High-performance liquid chromatography 
SEC Size exclusion chromatography 
SLS Static light scattering 
RALS Right angle light scattering 
DLS Dynamic light scattering 
PDI Polydispersity index 
MS Mass spectrometry 
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Introduction 
Carbonic anhydrases, CAs, are fundamental enzymes catalyzing the hydration of carbon 
dioxide (Chegwidden and Carter, 2000). There are 16 isoforms of "-CAs that are 
characterized in humans (Kalinin et al., 2016). Among them is CA VI, the only secreted 
isoenzyme, that is produced by serous acinar cells in parotid and submandibular glands 
and human mammary glands resulting in secretion into saliva and human milk, respectively 
(Parkkila et al., 1990; Karhumaa et al., 2001). CA VI is known to possess anti-caries 
functionality as it balances the pH in the dental plaque microenvironment (Kimoto et al., 
2006). It has also been shown to have single nucleotide polymorphism resulting in alteration 
in bitter taste perception (Padiglia et al., 2010; Feeney and Hayes, 2014). CA VI is also 
used as a biomarker in primary Sjögren’s syndrome (Pertovaara et al., 2011). It has also 
been stated that CA would have nerve growth factor-like characteristics as it might function 
as a trophic factor in the infant alimentary tract (Henkin et al., 1999a; Karhumaa et al., 
2001).  
Although milk and salivary CA VI isoenzymes have been studied parallelly with SDS-PAGE 
and Western blotting, there are no studies focusing solely on comparing both of the CA VI 
isoenzymes. As the amino acid sequences were analyzed with amino acid databases, they 
revealed 100% identity with human salivary CA VI, yet the sequenced polypeptides 
covered only 40% of the full-length CA VI sequence (Karhumaa et al., 2001). Thus, there 
still remains a possibility that the milk and salivary CA VI isoenzymes have structural 
differences. Considering the different pattern of polypeptide bands for milk and salivary 
CA VI in the SDS-PAGE gel, there might be variation in protein glycosylation as well. To 
date, the particle size of CA VI has not been reported. Prior data has suggested that human 
CA VI might possess oligomeric assemblies (Pilka et al., 2012), it was tempting to 
hypothesize that those structures exist, and they could be observed with the chosen 
methods in the current study.   
This study was conducted to provide additional information for molecular weight and 
particle size of milk and salivary CA VI as well as assessing the potential post-translational 
differences between milk and salivary CA VI. 
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Literature review 
Introduction to carbonic anhydrases 
Carbonic anhydrases, CAs, are essential enzymes catalyzing the hydration of carbon 
dioxide #$% & '%$ ()'#$*+ & ',(Chegwidden and Carter, 2000). The reaction 
mechanism can be categorized as SN2, nucleophilic substitution, when the Zn2+-bound 
hydroxide group attacks on CO2 followed by the bicarbonate displacement with water and 
finally, deprotonation of water to regenerate the hydroxide (Chegwidden and Carter, 2000). 
In all isoforms, the active site is located in the funnel-shaped cavity extending from the 
center of the protein to the surface (Stams and Christianson, 2000). The catalytic zinc atom 
is located at the bottom of this cavity coordinated by three histidine residues (Stams and 
Christianson, 2000). First, histidine ligands structurally stabilize the zinc-binding site and 
secondly, functionally maintain the reactivity of zinc-bound solvent for catalysis (Stams and 
Christianson, 2000). 
The superfamily of carbonic anhydrases 
To date, the superfamily of carbonic anhydrases consists of seven, genetically unrelated 
families of isoforms noted as "-, --, .-, /-, 0-,)1- and 2-CAs (Vullo et al., 2017). The 
distribution of the carbonic anhydrase families is presented in figure 1. "-CAs are present 
solely in vertebrates (Chegwidden and Carter, 2000). This "-family of isoforms is also 
present in many algae, plants and eubacteria (Chegwidden and Carter, 2000). In addition 
to "-CAs, plants and algae also encode for --, .-, /- and 2-CAs (Vullo et al., 2017). Marine 
diatoms, forming a major group of algae, encode for 0-CAs (Innocenti et al., 2010). CAs 
identified in bacteria belong to the "-, -- and .-CA-classes (Vullo et al., 2017).  
 
Figure 1 Schematic distribution of CA families in A) animals, B) plants and algae, C) protozoa and D) bacteria.  
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The remaining three isoforms are classified as carbonic anhydrase related proteins, 
CARPs, that are catalytically inactive, because these isoforms lack histidine residues 
forming the coordination bond to zinc atom (Aspatwar et al., 2010). Nevertheless, CARPs 
have a high sequence and structure similarity with other isoforms and are thus considered 
as a part of CA isoform family (Tashian et al., 2000). To date, three CARPs have been 
discovered: CARP VIII, CARP X and CARP XI (Tashian et al., 2000).  
Distribution and functions of 3-carbonic anhydrases 
 There are 16 isoforms of "-CAs, which have been characterized in humans (Kalinin et al., 
2016). Histidine residues, His-94, His-96 and His-119, are conserved within mammalian "-
CA isoforms, which stabilize the hydration of CO2 and catalysis of water and, thus, are 
important for hydration of CO2 (Stams and Christianson, 2000). These isoforms are involved 
in a variety of diverse physiological processes, such as respiration, acid-base balance, 
bone resorption and calcification, as this conversion from CO2 to bicarbonate is essential 
in animals (Chegwidden and Carter, 2000). Also, "-CA-isoenzymes take part in many other 
biological pathways including ion, gas and fluid transfer (Chegwidden and Carter, 2000). 
The distribution of the enzymatically active isoforms is presented in a schematic 
mammalian cell model (Fig. 2). There are five cytosolic CA-isoforms (CA I, CA II, CA III, CA 
VII and CA XIII), five membrane-bound isoforms (CA IV, CA IX, CA XII, CA XIV and CA XV), 
two mitochondrial isoforms (CA VA and CA VB) and finally, the secretory isoform CA VI that 
is found in saliva and milk (Innocenti, Scozzafava and Supuran, 2010).  
 
Figure 2 Distribution of !-CAs in an animal cell model. Cytosolic isoforms are CA I, CA II, CA III, CA VII and CA XIII. 
Membrane-bound isoforms are CA IV, CA IX, CA XII, CA XIV and CA XV. CA VA and CA VB are mitochondrial isoforms. 
To date, CA VI is found to be the only secreted isoform.  
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The subcellular location and functions for mammalian "-CAs are described subsequently, 
except secretory CA VI, which is introduced in the chapter ‘Carbonic anhydrase VI’. 
Cytosolic carbonic anhydrases  
Cytosolic CAs, CA I and CA II, are found in erythrocytes as they function as classical 
catalysts in carbon dioxide hydration (Frost, 2014). Physiologically, CA II has a higher 
activity compared with CA I, and thus can be considered more relevant in actual CO2-
hydration process (Frost, 2014). CA II is also widely present in kidneys (Brown et al., 1983). 
When investigating immunohistochemically stained rat tissue, CA II was observed in 
intercalated cells and in proximal tubules, the loop of Henle and principal cells found in 
collecting ducts (Brown et al., 1983). In addition, the uneven distribution of CA II due to the 
heterogenic development rate of the nephrons will partly explain the reduced capacity for 
urinary acidification, which is reported for infants born prematurely (Lönnerholm and 
Wistrand, 1983). CA III, however, differs from the other isoenzymes protecting cells from 
irreversible protein oxidation, as it has shown to have protective role against oxidative 
stress (Thomas and Mallis, 2001). CA III is present in skeletal muscle tissue and both of 
adipose tissues (Frost, 2014). Human CA VII was identified through genomic screening 
(Montgomery et al., 1991) and was later discovered to have a long, predominant form and 
a shorter form (Bootorabi et al., 2010). It was also localized in the colon, liver and skeletal 
muscle, and to some extent in the brain (Bootorabi et al., 2010). CA XIII was identified in 
2004 and localized to be residing in various human tissues, including thymus, small 
intestine, spleen, prostate, ovary, colon and testis (Lehtonen et al., 2004). 
Mitochondrial carbonic anhydrases 
CA VA and CA VB are localized in the mitochondria with varying expression in different 
tissues (Shah et al., 2000). CA VA was found to express only in liver, skeletal muscle and 
kidney, CA VB, conversely, was detected in most tissues (Shah et al., 2000). When 
inhibiting CA VA and VB, it has been found to reduce lipogenesis through a novel 
mechanism and these isoenzymes could thus be considered having potential for 
therapeutic applications (Poulsen et al., 2008).  
Membrane-associated carbonic anhydrases 
The membrane associated CAs in human include CA IV, CA IX, CA XII, CA XIV and finally 
CA XV (Innocenti, Scozzafava and Supuran, 2010). CA IV is shown to be present in the 
lung, kidney, heart, brain, the capillary of the eye and erythrocytes (Frost, 2014). It was also 
claimed to form a functional complex with Na+/bicarbonate co-transporter NBC1 to 
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maintain correct pH balance in retinal environment (Yang et al., 2005). Furthermore, recent 
evidence suggests that CA IV would also have a role in skin wound healing, as CA IV 
significantly accelerated wound re-epithelialization when introduced to the wound in zebra 
fish (Barker et al., 2017). CA IX and XII are limited in normal expression but are found to be 
tumor-related isoforms of "-CAs (Frost, 2014). For example, CA IX interacts with pH-
regulating sodium bicarbonate co-transporter (NBC1) and anion exchanger 2 (AE2) that 
are components of migration apparatus (Svastova et al., 2012). Thus, CA IX was shown to 
actively contribute to cell migration that is one of the factors promoting the metastatic 
cascade (Svastova et al., 2012). CA XII expression, however, has been showed to be in 
correlation with the positive prognosis in breast cancer (Barnett et al., 2008). When 
studying mRNA of CA XIV, it was highly expressed in brain and weaker signal was seen in 
colon, small intestine, urinary bladder, and kidney (Frost, 2014). The newest member of the 
membrane associated CAs, CA XV, was shown to be present in mouse kidney (Tolvanen 
et al., 2013). It provided an attractive example of adaptation in the terms of evolution, as 
the functions of CA XV seems to be taken over by CA IV (Tolvanen et al., 2013).  
Secreted carbonic anhydrases 
To date, only one secretory carbonic anhydrase isoenzyme, CA VI, has been distinguished. 
As this thesis is primary concentrating on CA VI, I will describe the structure and functions 
of human CA VI and non-human CA VI in more detail in the following chapter. 
Carbonic anhydrase VI  
Carbonic anhydrase VI is a secreted enzyme  that was first found in the late 1940’s (Rapp, 
1946). To date, CA VI is the only secretory isoenzyme found in mammals (Patrikainen et al., 
2016). As the literature of CA VI shows, the secretory isoenzyme has also been called 
‘gustin’ until it was proven to be the same protein as CA VI in the late 1990’s (Thatcher et 
al., 1998). Nevertheless, the name ‘gustin’  is still used occasionally when referring to CA 
VI in the scientific literature (Padiglia et al., 2010; Calò et al., 2011; Melis et al., 2013; 
Barbarossa et al., 2015). Although CA VI has been carefully studied in the past 60 years, 
the fundamental functions of the secretory isoenzyme still remain uncovered.  
In the following chapter, I will introduce the general properties considering human CA VI; 
its origin and locations in the human body and secretional alterations. Then, I will discuss 
the catalytic properties of CA VI as functional enzyme. Also, I will briefly introduce the key 
biological phenomena that CA VI is related in; dental caries, polymorphism, taste 
perception and finally Sjögren’s disease. I will also describe the gene and protein structure 
of CA VI. 
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In the second chapter I will introduce the essential findings of non-human CA VI; where CA 
VI is located in various animals and what are the main functions reported on CA VI; the 
dental caries model in mice, bitter taste perception studies by using mice and finally, the 
kidney disease model in pig. Then, I will briefly cover the theoretical aspects of used 
methods in my thesis.   
human carbonic anhydrase VI 
Human carbonic anhydrase VI is produced by serous acinar cells in parotid and 
submandibular glands resulting in secretion into saliva (Parkkila et al., 1990). It was later 
demonstrated that serous salivary glands, von Ebner’s glands, located in the posterior 
tongue among lingual muscle fibers, deliver CA VI to the immediate proximity of taste buds 
(Leinonen et al., 2001). This local secretion implies the connection between CA VI and taste 
bud function (Leinonen et al., 2001). The relation between CA VI and taste perception is 
described more detail in chapter ‘’ Carbonic anhydrase VI in taste perception’’. 
CA VI was first purified from human saliva in 1987 and considered a distinct form of a novel 
isoenzyme although CA VI was found to be genetically and immunologically related to CA 
II (Murakami and Sly, 1987). The secretion of CA VI into saliva is found to follow circadian 
periodicity together with "-amylase, even though it was independent of salivary secretion 
(Parkkila et al., 1995). When CA VI was measured from the human serum, the concentration 
varied greatly within individuals and circadian rhythm was not as evident compared with 
salivary CA VI (Kivelä et al., 1997).  As CA VI is abundant in human parotid saliva, CA VI 
isoenzyme was first thought to have an effect on regulating pH in saliva (Parkkila et al., 
1990), but was later found to have no significant correlation with pH buffering capacity, 
suggesting that CA VI is not directly regulating salivary pH (Kivelä et al., 1999).  
In human serum, CA VI was demonstrated to bound into IgG (Kivelä et al., 1997). This could 
prevent CA VI from protein degradation or alternatively, function as a targeting factor to 
guide CA VI to cells not expressing this isoenzyme (Kivelä et al., 1997). CA VI has been 
studied within different populations of both sexes. CA VI concentration in saliva was found 
to be somewhat lower in young women than young men (Kivelä et al., 1997; Kivelä et al., 
2003). CA VI production has also been studied in pregnant women (Kivelä et al., 2003). 
Pregnancy did not affect CA VI concentration in saliva even though the buffer capacity of 
saliva was discovered to be lower than in non-pregnant women (Kivelä et al., 2003). This 
further confirms that CA VI is not directly regulating salivary pH (Leinonen et al., 1999).  CA 
VI was also found to secrete from the mammary glands to human milk (Karhumaa et al., 
2001). When measuring the concentration of CA VI in human colostrum, the first secretion 
of mammary glands after giving birth, it was discovered to have a CA VI-concentration 
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approximately eight times higher compared with the concentration measured in mature 
milk collected 90 days postpartum (Karhumaa et al., 2001). The high concentration of 
colostral CA VI could recompense the low salivary CA VI in the infant alimentary tract and 
their incomplete salivary secretion (Karhumaa et al., 2001). CA VI is found to have similar 
characteristics than nerve growth factor NGF, thus this isoenzyme might function as a 
trophic growth factor in the infant alimentary tract (Karhumaa et al., 2001).  
The genetic structure of carbonic anhydrase VI  
CA 6 gene is located at chromosome 1 on the tip of the short arm (Sutherland et al., 1989). 
The sequence analysis has been executed for CA 6 gene in order to investigate its 
evolution (Patrikainen et al., 2017). Phylogenetic analysis showed that CA IX, XII, XIV and 
CA VI share a common ancestor proposing that the given isoenzymes appeared as a result 
of two whole genome duplications in the evolution of early vertebrates (Patrikainen et al., 
2017). As CA VI evolution was more carefully considered, a likely evolutive pathway was 
introduced resulting in varying CA VI domain structures (Patrikainen et al., 2017). First, it is 
supposed that exon coding for the cytoplasmic domain in ancestral CA VI was replaced 
by PTX-encoding exon (Patrikainen et al., 2017). Simultaneously, the transmembrane helix 
present in the common ancestor CA was transformed into an amphipathic helix changing 
the conformation of the evolving CA VI (Patrikainen et al., 2017). Later, as the PTX domain 
was lost, CA VI reached its final structure having an amphipathic helix at the C-terminus 
(Patrikainen et al., 2017). These conclusions were supported by four essential 
observations; exon lengths of transmembrane-helix-coding exon, the loss of the 
cytoplasmic domain in ancestor CA VI and PTX domain in mammalian lineage, 
rearrangement in glucose transporters near PTX domain and, finally, the abundance of PTX 
domain in non-mammalian CA VI (Patrikainen et al., 2017). This sequence of structural 
changes has ultimately resulted in the unique structure of CA VI consisting of catalytic CA 
domain and a amphipathic helix lacking the cytoplasmic domain (Patrikainen et al., 2017). 
However, this structural analysis has been performed by studying CA VI found in zebra fish 
that ultimately possesses a pentameric assembly with the pentraxin domain.  
The amino acid structure of carbonic anhydrase VI 
Human CA VI has a signal peptide that is first cleaved resulting in the mature form of CA 
VI; a 291-amino acids containing protein showing strong sequence similarity particularly to 
membrane bound isoenzymes (Supuran and De Simone, 2015). There are distinct 
properties in both amino- and carboxy-terminals. The amino-terminal region possesses a 
conserved active site, N-glycosylated site and cysteine residues forming a conserved 
disulphide bond (Supuran and De Simone, 2015). The carboxy-terminal region contains 
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both a unique sequence of 30 amino acids only found in CA VI as well as a recognition 
determinant for glycosyltransferases (Supuran and De Simone, 2015). 
Human CA VI has a molecular weight of 42 kD determined from saliva (Murakami and Sly, 
1987). Later, CA VI isoenzymes, both salivary and milk, have been determined as 42-kD 
proteins by Western blotting (Karhumaa et al., 2001). However, it was reported that 
deglycosylation of both salivary and milk CA VI, reduced their molecular size to 36 kD 
(Karhumaa et al., 2001). It was reported having two N-linked oligosaccharide side chains, 
an oligosaccharide linked into the amide nitrogen of asparagine residue (Leinonen et al., 
2001). These side chains terminate with GalNAc-4-SO4 (Hooper et al., 1995). The 
nonglycosylated milk CA VI isoenzyme was digested and sequenced with matrix-assisted 
laser desorption/mass spectrometry and ultimately, shown to have 100% identity compared 
with salivary CA VI and the coverage being 40% of the full-length CA VI (Karhumaa et al., 
2001). It was speculated that as the milk CA VI amino acid sequence was only 40% covered 
of salivary CA VI, there is a possibility that salivary CA VI and milk CA VI might possess 
alternating amino acid structures (Karhumaa et al., 2001).  
The crystallized structure of the catalytic domain of CA VI, aa 32-279, has been published 
at 1.9 Å resolution (Pilka et al., 2012). The catalytic domain, including the amino acids 21-
290 (Homo sapiens carbonic anhydrase VI mRNA, GenBank entry 21706434), was 
subcloned into a vector with His-tag and after transforming, culturing, lyzing and purifying 
the protein, His-tag was removed from the catalytic domain (Pilka et al., 2012). When 
crystallized, it was shown to assemble as orthorhombic space group P212121, P describing 
the lattice being a primitive, rectangular shape and 212121 depicting the symmetry group 
of its configuration in three-dimensional space (Pilka et al., 2012). 
The catalytic domain of human CA VI was found to have two molecules in a single 
asymmetric unit (Pilka et al., 2012). The asymmetric unit forms a dimer structure, as the 
active sites of the domains are juxtaposed towards the dimeric center, facing each other 
(Pilka et al., 2012). 11 hydrogen bonds are formed at the dimeric interface, burying a 
statistically significant area of accessible surface that exceeds the average for biological 
dimers (Pilka et al., 2012). When analyzed with size-exclusion chromatography, two 
equally-sized peaks were detected and thus argued to be the dimeric and monomeric 
assemblies of the catalytic domain of the recombinant CA VI (Pilka et al., 2012). This novel 
information about the dimeric occurrence of CA VI could explain its functionality in vivo, like 
it has been hypothesized for CA IX (Alterio et al., 2009) and CA XII (Whittington et al., 2004). 
However, it has to be emphasized that only the catalytic domain, aa 32-279, were 
crystallized (Pilka et al., 2012). For CA IX, the dimerization is mediated by Cys 41-Cys 41-
disulphide bond that interconnects two monomers (Alterio et al., 2009). Due to the 
  9 
orientation of the monomers, both active sites exposed to extracellular space for efficient 
CO2-hydration (Alterio et al., 2009). This is consistent with the tissues reported having 
expression or over-expression of the CA IX (Alterio et al., 2009). For CA XII, the catalytic 
domain is also found to obtain a dimeric structure (Whittington et al., 2004). Dimerization is 
predicted to occur in the transmembrane helices as they contain the dimerization motifs 
GXXXG and GXXXS (Whittington et al., 2004). Still, only the catalytic, globular domains of 
CA XII and CA IX have been able to crystallize leaving the whole structure, thus the external 
structures undiscovered (Whittington et al., 2004; Alterio et al., 2009).  
The dimer formation has been previously reported on sheep, when ovine tear secretion was 
analyzed with Western analysis and CA VI was assumed to be the in dimeric state 
considering its fitting molecular weight (Ogawa et al., 2002). However, other methods were 
not used to verify this assumption. Also, an alternative form of CA VI, a CCAAT/Enhancer-
Binding Protein Homologous Protein-dependent stress-inducible form (CHOP-inducible 
form), has been reported on murine cell culture studies (Sok et al., 1999; Matthews et al., 
2014). In response to stress, an alternative CA VI, CA VI-b is encoded and retained in the 
intracellular space (Sok et al., 1999). CA VI-b was sequenced and found to lack a signal 
peptide and, thus, is not predicted to encode a secretory protein (Sok et al., 1999). Still, as 
the CA VI-b was sequenced to contain all the known residues contributing to the active site 
and most of the residues were conserved among other CAs, it can be assumed that it is 
very likely for CA VI-b to have carbonic anhydrase and esterase activities (Sok et al., 1999). 
Activation of endoplasmic reticulum unfolded protein stress response pathway leads to 
expression of the CA VI-b from unknown promoter (Matthews et al., 2014). This unknown 
promoter is regulated by CHOP as it acts as a downstream regulator activating 
proapoptotic effectors (Sok et al., 1999). Thus, a CHOP-regulated induction of CA VI-b was 
thought to be proapoptotic (Sok et al., 1999). Later, however, it was reported that CA VI-b 
solely has little influence on cell viability (Matthews et al., 2014). CA VI-b was reported 
functioning as a part of pro-survival branch of the CHOP-signaling but still, it is suggested 
that the role of CA VI-b is more complex in cell death decisions (Matthews et al., 2014). For 
more specific functions for CA VI-b, it was shown that CA VI-b is necessary for mediating 
the beneficial properties of the brain derived neurotrophic factor BDNF in hypoxic neuron 
survival (Matthews et al., 2014). 
The domain was found to assemble in the canonical CA-fold having several, short "-helices 
and ß-sheets surrounding the ten-stranded ß-sheet located in the center (Pilka et al., 2012). 
It has a conserved, intramolecular disulphide-linkage between cysteines 42 and 224 that 
stabilizes the active site, so that the Zn2+-bound hydroxide is oriented for catalytic reaction 
(Pilka et al., 2012). The disulphide linkage identical to CA VI can be found also in the other 
CA-structures (Pilka et al., 2012). When CA VI was aligned with CA I-CA XIV, it was 
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predicted to share high sequence identity with membrane-bound isoenzymes CA IV and 
CA XIV in addition to cytosolic isoenzyme CA II (Pilka et al., 2012). Due to sequence 
insertions and deletions, the backbone of CA VI was found to differ slightly from other CA-
isoenzymes as three varying regions were identified (Pilka et al., 2012).  
Catalytic properties of CA VI 
For human CA VI, both reactions, hydration CO2 and dehydration of bicarbonate, have 
been investigated in terms of their specific activity rates. Human CA VI has a maximum 
value of 456 7 89: ;<=  for kinetic constant >?@ABC  when dehydrating bicarbonate ions are 
conveyed into CO2 and water (Leinonen, 2008). The half-saturated concentration of 
bicarbonate, KM, is significantly lower when compared with other CAs having the KM<20 
mM (Leinonen, 2008). However, it resembles the concentration of bicarbonate in saliva and 
milk that possibly suggests the capacity for CA VI to catalyze bicarbonate with high kcat, 
respectively (Leinonen, 2008).  
When considering the hydration reaction, the catalytic efficiency, >?@ABC , for human CA VI is D56 7 89: ;<= , which is one-third of the fast, cytosolic CA II, but KM of  has a value close to 
other CAs, with few exceptions (Nishimori et al., 2007). Its turnover rate kcat is E5D 7 89F ;=, 
which is a somewhat moderate value in comparison with other CAs (Nishimori et al., 2007). 
Uniquely assembled amino acid residues explain the activity of CA VI; threonine and serine 
residues near the conserved proton shuttle residue His64 might be bulkier compared with 
alanine, present in highly efficient CA II in the given location, so that Ser/Thr residues might 
result in interfering in the movement of His64 (Nishimori et al., 2007). CA VI has residues 
typical for other CAs as well, which are involved in binding activators or inhibitors (Nishimori 
et al., 2007). Also, CA VI has characteristic residues near zinc ligands affecting its activity 
(Nishimori et al., 2007). Interestingly, CA VI is found to be the most sensitive to bicarbonate 
and chloride inhibition suggesting towards the biomolecular environment of the given 
enzyme containing alterable amounts of proteins and anions (Nishimori et al., 2007).  
Human CA VI is found to activate cAMP PDEase at the physiological concentration, but the 
mechanism differs from Ca2+-dependent-calmodulin activation (Law et al., 1987). The 
PDEase activation by CA VI might explain how CA VI affects taste function, as cAMP 
PDEase is an important regulator in taste perception (Law et al., 1987). However, this 
research has not been further continued and additional data has not been discovered.  
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Recently, the melting temperature of salivary CA VI has also been studied (Kazokaite et al., 
2015). For native, salivary CA VI the melting point was reported being +53,6 °C by inhibitor 
binding method Fluorescence Thermal Shift Assay, FTSA, which determines thermal 
stability via fluorescent probes while the temperature is steadily increased (Kazokaite et 
al., 2015). 
Carbonic anhydrase VI and caries 
Human CA VI has been found to have anti-caries characteristics; caries-free children 
expressed higher CA activity than the children having active caries (Szabó, 1974). Also, 
negative correlation between CA VI concentration and poor oral hygiene was discovered 
by investigating the number of decayed, missing or filled teeth (DMFT index) within 
individuals (Kivelä et al., 1999). Low CA VI concentration was measured with individuals 
having a low DMFT index value (Kivelä et al., 1999). Salivary CA VI was found to be a 
natural component of enamel pellicle and shown to be functional and active on the enamel 
surface (Leinonen et al., 1999). CA VI is suggested converting bacterial plaque-derived 
H+-ions with salivary bicarbonate into carbon dioxide and water, and thus preventing the 
acidification of the microenvironment (Leinonen et al., 1999). As the phenomena were 
further investigated, salivary CA VI was inhibited with acetazolamide resulting in the lower 
pH value of dental plaque (Kimoto et al., 2006). This further suggests that salivary CA VI 
penetrates the plaque and neutralizes acidic H+-ions with salivary bicarbonate in the given 
microenvironment and thus, can be considered as an anti-caries protein (Kimoto et al., 
2006). 
Polymorphism of carbonic anhydrase VI 
As the nuanced functions of CA VI still remain unclear, studies have also been carried out 
to discover whether single nucleotide polymorphisms (SNPs) occur in the coding region of 
CA 6 (Peres et al., 2010; Aidar et al., 2013). Three SNPs have been reported being present 
at the coding region of CA 6 (Peres et al., 2010). Buffer capacity or caries susceptibility 
had no statistically significant difference between the groups (Peres et al., 2010). However, 
a positive association between the buffer capacity and rs2274327 (C/T) polymorphism was 
observed when allele T and genotype TT were significantly less frequent among individuals 
with high buffer capacity (Peres et al., 2010). 
 It was suggested that instead of coding for C allele resulting in threonine, allele T results 
in coding Met that ultimately disrupts a highly conserved short ß-sheet (Peres et al., 2010). 
This change is likely to interfere with the function of CA VI, like buffer capacity (Peres et al., 
2010). Genotype TT of rs2274327 (C/T) polymorphism was also associated with 
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significantly lower salivary CA VI concentration (Aidar et al., 2013). Still, the enzymatic 
activity of CA VI showed no significant differences between groups with altering 
polymorphisms (Aidar et al., 2013). It is proposed that as rs2274327 allele T lies at the site 
of O-glycosylation, it is very likely to have this site glycosylated (Aidar et al., 2013). O-
glycosylation has been shown to be a protective signal against proteasomal degradation 
(Guinez et al., 2008).  
Carbonic anhydrase VI in taste perception 
Carbonic anhydrase VI has been considered as a salivary growth factor that maintains the 
function of taste buds (Henkin et al., 1999a). Inhibition of CA VI synthesis is correlated with 
the abnormal development of taste buds resulting in the loss of taste function (Henkin et 
al., 1999a). By treating with exogenous zinc, CA VI content was increased in parotid saliva 
and in addition, patients exhibited improvement in taste and smell acuity (Henkin et al., 
1999b). It was discussed that zinc would act as a gene transcription stimulant resulting in 
the synthesis and secretion of CA VI (Henkin et al., 1999b). It is suggested that CA VI acts 
as a trophic factor promoting growth and development of taste buds while affecting taste 
bud stem cells (Henkin et al., 1999b). The long-term exposure of low pH of epithelial cells 
has been found to lead to apoptosis, so it is suggested that  CA VI may protect taste buds’ 
taste receptor cells (TRCs) from apoptosis by regulating their pH (Leinonen et al., 2001). 
Proton-gated potassium channels are inactivated because of acid stimuli depolarizing the 
TCRs (Kinnamon and Roper, 1987). CA VI might neutralize excess H+-ions in the taste bud 
microenvironment thus accelerating the recovery of proton-gated potassium channels 
(Leinonen et al., 2001). 
SNPs of CA 6 have been investigated in terms of altering taste perception (Padiglia et al., 
2010). SNP in CA 6 coding region, rs2274333 (A/G) resulting in Ser90Gly substitution in 
amino acid sequence, has been investigated whether it would have an effect on bitter taste 
perception (Padiglia et al., 2010). The SNP rs 2274333 affecting exon 3 of the CA 6 gene 
seems to be altering the capacity of CA VI to bind zinc (Padiglia et al., 2010). The genotype 
AA, associated with fully functional protein, was statistically shown  to be associated with 
high responsiveness to PROP, a well-known substance for tasting the bitter, and 
controversially, individuals expressing GG, associated with a disruptive form of CA VI, 
would have the lowest responsiveness for PROP (Padiglia et al., 2010). Additionally, the 
alteration within CA VI may be related to differences in papillae densities and oral 
chemosensory abilities among alternating phenotypic groups of PROP (Padiglia et al., 
2010). However, no significant differences were observed in fungiform papillae density 
considering any SNPs of CA 6 (Feeney and Hayes, 2014). 
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The connection between PROP and CA VI has been debated. Another study suggested 
that CA 6 polymorphism would associate with salt perception rather than PROP (Feeney 
and Hayes, 2014). It has been shown that saltiness intensity increases as a function of 
PROP intensity, thus indicating that the ratio between PROP and salt might not be the 
optimal choice to define PROP functionality (Feeney and Hayes, 2014).  
Carbonic anhydrase VI as a marker for Sjögren’s syndrome 
Primary Sjögren’s syndrome (pSS) is a chronic rheumatic disease having the characteristic 
symptoms of dryness of the eyes and mouth, and possible extraglandular symptoms 
(Pertovaara et al., 2011). In pSS, abundant autoantibody production occurs as a sign of 
autoimmunity and it can be clinically determined by observing renal manifestations 
(Pertovaara et al., 2011). As anti-CA antibodies have been suggested being pathogenic 
when involved in the formation of renal manifestations, anti-CA antibodies were measured 
together with serum creatinine, sodium and potassium as well as urinary excretion 
substances (Pertovaara et al., 2011). The inverse correlation between the concentration of 
anti-CA-antibodies in the serum and serum sodium levels could imply that CA VI is one of 
the significant regulators of acid-base homeostasis in pSS patients (Pertovaara et al., 
2011). Moreover, anti-CA-antibodies, including anti-CA VI, correlated significantly with 
urinary pH in pSS patients, thus suggesting that these anti-CA-antibodies might be 
associated in renal acidification capacity (Pertovaara et al., 2011). Detection of 
autoantibodies to CA VI in the early stage of pSS might imply the diagnostic relevance that 
CA VI could provide, in addition to the markers Ro and La (Matossian and Micucci, 2016).  
Localization of non-human carbonic anhydrase VI  
Various species have been used for localizing CA VI within different tissues. To date, CA 
VI has been purified from the saliva and parotid glands of several mammals, like sheep 
(Fernley et al., 1979), rats (Feldstein and Silverman, 1984), humans (Murakami and Sly, 
1987), cattle (Asari et al., 2000), swine (Nishita et al., 2001), mice (Kimoto et al., 2004)  and 
dogs (Kasuya et al., 2007).  
In sheep, measurable amounts of CA VI were found in parotid, submandibular and salivary 
glands by radioimmunoassay (Fernley et al., 1988). In rat, CA VI was discovered 
immunohistochemically to be present in the serous acinar cells, ductal cells and ductal 
content of von Ebner’s glands and in the demilune, ductal cells plus ductal content of rat 
lingual mucous glands (Leinonen et al., 2001). Moreover, CA VI was found to be present in 
the serous acinar cells and duct cells of tracheobronchial glands and in the secretory cells 
and the base of the ciliated cells of the tracheobronchial surface epithelium in addition to 
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Clara cells residing on the bronchiolar surface epithelium (Leinonen et al., 2004). When 
considering the presence of CA VI in cattle, it was shown by RT-PCR and 
immunohistochemical methods that bovine mammary gland together with salivary and 
lacrimal glands synthetize CA VI and, thus it is also found in cow milk and tear fluid (Kitade 
et al., 2003). Also, positive signs were seen in the bovine stratified epithelium of esophagus, 
in the stratified epithelium of bovine forestomach, the mucous cells of upper glandular 
region of the large intestine, and finally, in some ductal cells of submandibular, 
monostomatic sublingual and esophageal glands (Kaseda et al., 2006). Afterwards, it was 
shown by RT-PCR and ELISA that CA VI is present also in bovine liver (Nishita et al., 2007).  
In swine, however, CA VI was determined by ELISA to be present in saliva, parotid gland, 
sublingual gland and submaxillary gland, but in serum, bile, seminal plasma, and finally, 
gall bladder, too, which was observed immunohistochemically to be present at the 
columnar epithelial cells lining the gallbladder (Nishita et al., 2011). Still, CA VI measured 
from serum and gallbladder was only a small fraction compared with the concentration 
measured in parotid gland demonstrating that the highest and most significant 
concentration was found in parotid gland (~440 Gg/1 g wet tissue), and moderate 
concentrations (~100 Gg/1 g wet tissue) pancreas, lung, bile, seminal plasma and 
colostrum (Nishita et al., 2011). Also, CA VI was localized in the epithelial cells of the renal 
straight distal tubules (Nishita, Yatsu, Murakami, et al., 2014). In mice, CA VI was 
immunohistochemically observed in acinar cells of, in the duct contents of the anterior 
gland of nasal septum, in the lateral nasal gland and ultimately, in the mucus covering the 
respiratory and olfactory mucosa and in the lumen of the nasolacrimal duct (Kimoto et al., 
2004). By using immunohistochemical methods and both RT-PCR and q-PCR, canine CA 
VI was localized in mucosal epithelial cells, in the cytoplasm of serous acinar and ductal 
epithelial cells of the nasal mucosa and glands including the vestibule of the nose (Kasuya 
et al., 2007).  
In addition to the mammalian animal models, CA VI has been characterized in pufferfish 
Tagifugu rubripes, and by comparing semi-quantitative RT-PCR and q-PCR results 
simultaneously, the highest expression for CA VI was found in liver, and after that kidney, 
heart, blood and gill also showed moderate expression levels (Sumi et al., 2018). By 
investigating liver tissue more carefully by using fluorescence-in-situ-hybridization FISH, 
the expression might be seen within hepatocytes (Sumi et al., 2018). However, it has been 
shown that in the case of zebra fish, the non-mammalian CA VI is present with a pentraxin 
(PTX) domain, an inflammation regulating multimeric protein complex (Patrikainen et al., 
2017). CA VI binding PTX is most closely related to SAP and CRP, that are fundamental 
fluid-phase pattern recognition molecules functioning in innate immune system reactions 
(Bottazzi et al., 2016). When the distribution of CAVI-PTX in zebrafish was studied, 
immunohistochemical staining showed a high presence of CA VI in skin, heart, gills, and 
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the swim bladder (Patrikainen et al., 2017). In detail, CA VI was observed on the cell surface 
(Patrikainen et al., 2017). 
Functions of carbonic anhydrase VI in non-human species 
To date, published non-human CA VI studies are somewhat focused on measuring and 
localizing CA VI (Fernley et al., 1979; Feldstein and Silverman, 1984; Fernley et al., 1988; 
Asari et al., 2000; Karhumaa et al., 2001; Leinonen et al., 2001; Nishita et al., 2001, 2011; 
Kasuya et al., 2007; Patrikainen et al., 2017; Sumi et al., 2018). However, several studies 
show a variety of physiological phenomena that CA VI is part of. Transcriptomic responses 
and histological alterations in the submandibular gland, the stomach and duodenum of CA 
6-deficient mice have been reported (Pan et al., 2011). This knock-out mouse model for CA 
VI deficiency has been useful to demonstrate changes in gene expression morphology in 
lower airways (Patrikainen et al., 2016)  and similarly, CA 6 -deficient mice were used on 
studying caries development induced by Streptococcus mutans (Culp et al., 2011). A 
knock-down zebra fish model was established for determining behavioral and 
morphological changes due to transient lack of CA VI (Patrikainen et al., 2017).  
Still, there are certain physiological phenomena associated with CA VI that have been 
investigated in the animal model. CA 6-deficient mice were used to examine bitter taste 
perception (Patrikainen et al., 2014). Although no morphological changes were detected 
in the routine light microscopy of fungiform papillae, CA 6-deficient mice had altered 
behavior for bitter taste (Patrikainen et al., 2014). Compared with the wild type, behavioral 
monitoring showed that CA 6-deficient mice preferred bitter quinine solution (Patrikainen et 
al., 2014). This suggests that CA VI might have a role in bitter taste avoidance (Patrikainen 
et al., 2014). They also discovered that Car6-/- mice had a lower consumption of salty NaCl-
solution compared with the wild type (Patrikainen et al., 2014).  
Another mice model study showed how CA VI was also found to be dependent on Zn2+T4-
mediated Zn2+-transport, a direct Zn2+ transport from the cytoplasm into the trans-Golgi 
network, to maintain its stability (McCormick and Kelleher, 2012).  
As a secretory protein, CA VI is transferred via exocytosis to the mucus on olfactory and 
respiratory mucosa from acinar cells of nasal mucosa (Kimoto et al., 2004). CA VI secretion 
was detected to be dependent on vesicle associated membrane protein 8, VAMP8 (Wang 
et al., 2007). By using a VAMP8-knock-out line of mice, they were able to show 
immunohistochemically and by EM analysis that acinar cells had evenly distributed CA VI 
within the cytoplasm compared with the wild type that had CA VI restricted to the apical 
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side of the acinar cells (Wang et al., 2007). This suggests that VAMP8 has a key role in 
regulating secreted proteins in murine acinar cells (Wang et al., 2007).  
CA VI has also been considered as a biomarker for swine kidney diseases (Nishita et al., 
2014). By measuring the levels of CA VI from diseased and wild type pigs by ELISA and 
executing a statistical analysis of Dunnett’s multiple comparison test, it was postulated that 
CA VI could serve as a potential biomarker for kidney diseases as it was increased when 
the epithelial cells of the renal straight distal tubules were damaged (Nishita et al., 2014).  
Used methods for determining biochemical and biophysical characteristics of 
CA VI 
In the next chapter, I will briefly explain the theory of the study methods used in this thesis 
and why these methods were chosen to study human CA VI. First, I will discuss the affinity 
chromatography for protein purification. Then, I will continue with theoretical introduction to 
high performance liquid chromatography as well as to static and direct light scattering. 
Affinity chromatography for protein purification 
The specific affinity chromatography used for CA VI purification was developed originally 
for CA II purification (Wolpert et al., 1977) and subsequently it has been used in numerous 
CA VI studies (Law et al., 1987; Parkkila et al., 1990; Parkkila et al., 1995; Karhumaa et al., 
2001; Leinonen et al., 2001). Since it is considered as commonly accepted practice among 
researchers, this method was chosen to purify native CA VI from saliva and milk.  
 
High performance liquid chromatography 
High performance liquid chromatography (HPLC) is a separation method for a mixture of 
different compounds where the separation method is chosen due to the nature of the 
studied sample. Considering the aim of the study, to compare the structures of human 
salivary and milk CA VI, size-exclusion was selected as a suitable method for investigating 
the structural properties of the enzymes obtained from both sources. Size-exclusion 
chromatography is based on the porous structure of the stationary phase beads, which will 
adsorb the smaller molecules thus elongating their retention time (Moldoveanu and David, 
2013). The larger molecules are not retained as they cannot penetrate into the pores and 
are, thus, eluted earlier (Moldoveanu and David, 2013). Based on the relation of protein’s 
molecular size, the Stokes radius and the shape of the particle, elution volume is increased 
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as the particle size decreases (Slotboom et al., 2008). SEC is commonly used for 
determining the molecular weight of a studied particle (Slotboom et al., 2008).  
 
Figure 3 The schematic description of the size-exclusion process. The column packed with chemically and physically 
inert beads, which are porous and thus adsorbing smaller particles of the sample. This stationary phase separates sample 
molecules according to their size, as the largest particles have the shortest retention time and the smallest particles 
having the longest retention time. 
In SEC analysis, the flow rate of the sample, the pressure of the column and temperature 
can be adjusted to meet the required physical and chemical circumstances. Separation of 
the sample particles can be improved as the flow rate is decreased (Netopilík, 2017). The 
separation power of the studied particles will increase since molecules are able to 
compensate for the decreased rate of transversal diffusion (Netopilík, 2017). Also, the 
equilibrium state of the molecules in and outside of the porous beads of the stationary 
phase is more properly reached since they are given enough time to set (Netopilík, 2017). 
To overcome the resistance offered by the packed beads in the column, a suitable pressure 
must be provided to the mobile phase (Striegel et al., 2009). Generally, constant-flow 
reciprocating pumps are used as the constant-pressure pumps can suffer from changes 
affecting the column backpressure, like temperature-derived flow variations within the 
column (Striegel et al., 2009). Other specifications central to the pumping system are 
repeatability, short-term precision, pump pulsation, drift and flow rate accuracy (Striegel et 
al., 2009). Repeatability depicts the ability of resetting the pump to the exact flow rate 
repetitively, short term precision depicts how the precise and consistent is the volume 
output of the pump over time, pump pulsation occurs as operational functions like piston 
movement cause flow changes, drift measures the continuous changes in the pump output 
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over longer periods of time and finally, pumping accuracy reports the preciseness of the 
pump to deliver the exact flow rate that is set at the system (Striegel et al., 2009).  
Commonly in SEC, the temperature is increased to improve sample solubility (Striegel et 
al., 2009). Still, many analysis are performed out of room temperature because of their 
nature; for example biological samples might be susceptible to degradation or 
disassembly at high temperatures (Striegel et al., 2009). Within a good solvent, however, 
the particle size is changed very little with the temperature (Striegel et al., 2009). Even 
though the temperature has only a minor influence on the slope and position of the molar 
mass calibration curve, these small curve shifts will ultimately have a significant effect on 
the accuracy of the results (Striegel et al., 2009). Thus, large temperature fluctuations 
should be avoided in SEC analysis (Striegel et al., 2009).  
In the given study, LC-10Ai HPLC isocratic pump was used to maintain pressure during 
the analysis as it offers low pulsation performance and highly reproducible analyses 
(Shimadzu corporation, 2018).  
Static light scattering 
Static light scattering (SLS) measures the molecular weight of a macromolecule using the 
relationship between molecule’s scattered light intensity and molecular weight and size 
(Malvern Instruments Ltd., 2014). SLS is based on the fundamental Rayleigh relationship,  
HIJ K LMNMOPQRSTUVW X LMNMOPYZ[[UR K \ L]^]_P% `a# 
in which bcbd is the ratio of scattered light at angle 2 and the incident light for the sample, ebcbdfQRSTUVW, and the buffer, ebcbdfYZ[[UR, are subtracted. K is a constant depending on the 
refractive index of a solution without studied particles present, the used wavelength and 
the scatter angle 2, and the distance between the studied particle and the detector; gWgh is 
a specific refractive index increment for the studied protein; `a describing the molecular 
mass of the studied protein; # is the concentration of the protein (Slotboom et al., 2008).  
These will be resulting in HIJ, a parameter describing the excess scattered light due to the 
size of the studied protein (Slotboom et al., 2008).  
  19 
Molecular weight `a of a studied macromolecule can be estimated in different ways 
(Slotboom et al., 2008). In the two-detector method, the usage of parameter gigh that relates 
changes in the UV absorbance intensity of the studied solution to the studied protein 
concentration, enables computing the molecular weight for the studied macromolecule 
(Slotboom et al., 2008). Alternatively, the molecular weight of a studied macromolecule can 
also be retrieved by using retention volumes for standard proteins with known molecular 
weights (Slotboom et al., 2008). After converting the molecular weights to a logarithmic 
scale they can be plotted by their specific retention volumes and, thus, unknown molecular 
mass can be calculated by its known retention volume (Malvern Instruments Ltd., 2014).   
Right-angle light scattering (RALS) is an instrument measuring the intensity of scattered 
light at 90° to the incident light beam (Malvern Instruments Ltd., 2014). The molecular 
weight of the studied protein is directly calculated from measured intensity and sample 
concentration (Malvern Instruments Ltd., 2014). Due to 90° angle, any noise created by the 
change of the refractive index is minimized and, thus, it provides an excellent sensitivity 
and signal-to-noise ratio (Malvern Instruments Ltd., 2014). In addition, it is well-suited for 
estimating the size of proteins, generally having the diameter of <15 nm, as the 
measurement assumes that intensity is the same in both 0° and  90° angle (Malvern 
Instruments Ltd., 2014). For larger molecules, the assumption is incorrect as they display 
significant angular dependence considering the light that it scatters (Malvern Instruments 
Ltd., 2014).   
Dynamic light scattering 
Dynamic light scattering, DLS, is a method based on the essential property of light 
scattering, as the electromagnetic waves will induce electronic distortion that will be 
emitted in varying directions (Panchal et al., 2014). The scattering of light is depending on 
multiple parameters; (1) the homogeneity of particles, (2) their refractive index relative to 
surrounding medium and (3) particle shape and size (Jonasz and Fournier, 2007).  To 
estimate the sample homogeneity, the polydispersity index, PDI, compares the absolute 
standard deviation of the particle size distribution to the mean, creating the relative 
polydispersity (Nobbmann, 2014). The overall polydispersity is converted into 
polydispersity index PDI which is calculated as a square of light scattering polydispersity 
(Nobbmann, 2014). This is a value for estimating the degree of uniformity of a distribution; 
for an ideally uniform sample, polydispersity index PDI would be 0.0 (Nobbmann, 2014). 
The used apparatus in this study, Malvern Zetasizer Nano (Malvern Instruments Ltd., 
Worcestershire, UK), suggests that samples having a greater value than 0,7 are highly 
polydisperse and, thus, are perhaps unsuitable for DLS measurements (Malvern 
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Instruments Ltd., 2008). The range of 0,08-0,7 is considered the best operational area for 
the used algorithms in Malvern Zetasizer Nano apparatus (Shaw, 2018).  
In DLS, particles’ Brownian motion is measured and subsequently used for calculating the 
hydrodynamic diameter with Stokes-Einstein equation (Malvern Instruments Ltd., 2008). 
DLS illuminates particles with a laser so that intensity fluctuations of scattered light can be 
analyzed (Malvern Instruments Ltd., 2008). This type of scattering is referred to as 
quasielastic light scattering (Striegel et al., 2009). In DLS, the time-dependent fluctuations 
of scattered light are measured, whereas in SLS time-averaged fluctuations of scattered 
light are of interest (Striegel et al., 2009). In this thesis, the used DLS apparatus, Malvern’s 
Zetasizer NZ uses a digital correlator to compare the speckle patterns of signal intensity of 
particular part at one point in time (Malvern Instruments Ltd., 2008). With similar Brownian 
motion the intensity correlation is high within time points (Malvern Instruments Ltd., 2008). 
As the Brownian motion of the larger particles are minor compared with smaller particles it 
can be detected as a slow fluctuation of the intensity of the speckle pattern compared to 
smaller and thus faster fluctuating particles (Malvern Instruments Ltd., 2008). Ultimately, 
the correlation function for different-sized particles can be measured and used for the size 
determination of the studied particle (Malvern Instruments Ltd., 2008). The diffusion 
coefficient and the hydrodynamic radius can be measured and, thus, the diameter of the 
studied particle can be computed (Panchal et al., 2014). DLS analysis can be combined 
with SEC, in-line DLS, as it measures the particle size in the size-determined order, or it 
can be done solely using a separate DLS apparatus, batch DLS. Both types of DLS were 
used in this thesis. 
Results of batch DLS can be presented as intensity, volume or number distributions 
(Malvern Instruments Ltd., 2008). The peak area of the intensity distribution describes the 
scattering intensity of the given particle (Malvern Instruments Ltd., 2008). Since the large 
particles are able to scatter more light than smaller particles due to greater surface area, 
the scattering intensity of a particle is proportional to the sixth power of the particle diameter 
(Malvern Instruments Ltd., 2008). Based on the intensity distribution, a volume distribution 
can be generated that can be further computed into number distribution (Malvern 
Instruments Ltd., 2008). Number distribution depicts the peak are by the particle 
prevalence of the sample, e.g. equally-sized peaks indicate to an equal number of both 
samples (Malvern Instruments Ltd., 2008). Volume distribution depicts peak area by the 
particle’s volume (Malvern Instruments Ltd., 2008). Similar to intensity distribution, larger 
particles have greater volume than smaller particles, thus creating a larger peak area for 
greater particles and minor peak area for smaller particles (Malvern Instruments Ltd., 
2008). In this study, volume distributions are analyzed for determining the fundamental size 
of the CA VI isoenzyme. 
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The hydrodynamic diameter will not depend solely on the core size of the particle (Shaw, 
2018). It is also affected by the ionic concentration of the sample medium or particle’s 
surface structures (Shaw, 2018). Low ionic concentration creates an electric double layer 
of ions that decreases diffusion speed and thus, leads to larger, apparent hydrodynamic 
diameter (Shaw, 2018). Additional surface structures will affect diffusion speed, too (Shaw, 
2018). Adsorbed polymers projecting out from the particle surface will reduce the diffusion 
speed and also lead to apparently larger size (Shaw, 2018). Finally, for non-spherical 
particles, DLS will measure the diameter of a sphere having the same average translational 
diffusion coefficient as the non-spheroid particle (Shaw, 2018). Taken together, all of the 
previously described phenomena can change the apparent hydrodynamic diameter by 
several nanometers (Shaw, 2018).  
For determining the melting point of a studied protein, an increase in hydrodynamic radius 
and scattering intensity indicates the presence of denatured protein aggregates (Malvern 
Instruments Ltd., 2008). Thus, batch DLS offers a sufficient method for measuring the 
stability of a studied protein since the temperature can be steadily increased to desired 
value (Malvern Instruments Ltd., 2008).  
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Objectives 
The overall purpose of this research is to discover the potential oligomeric structure of milk 
and salivary CA VI. Also, it is desired to determine whether the human salivary and milk CA 
VI-proteins have differing glycosylations within their structures. In addition, the melting 
point for CA VI will be studied. 
The used methods include: 
•% Affinity chromatography 
•% High-performance liquid chromatography with static and dynamic light scattering 
•% Batch dynamic light scattering 
•% Mass spectrometry 
These methods should provide sufficient information for the assembly of human CA VI 
protein, and, to gain additional information of the essential structure of both salivary and 
milk CA VI, the melting point for the CA VI and, lastly, their potential differences considering 
post-translational modifications. 
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Materials and methods 
Salivary CA VI 
Salivary CA VI isoenzyme, for both HPLC-DLS analysis and batch DLS analysis, were 
collected in two batches due to insufficient amount of protein after the first batch was 
purified in terms of CA VI. All the used reagents, solutions prepared and used in the 
protocol are more carefully described in Appendix 1. Thus, only the given solution names 
are used in the ‘Materials and methods’ -section. For CA VI purification from milk and saliva, 
the original protocol of Murakami and Sly used in CA VI purification was followed (Murakami 
and W S Sly, 1987).  
Saliva collecting 
First, 100 ml and 300 ml of human saliva was collected for the purification of the CA VI 
isoenzyme. Volunteers expectorated into an ice-cold centrifuge tube, which contained 2 ml 
of collecting buffer (0,1 M TRIS, 0,2 M Na2SO4, 0,2 M Benzamidine, pH 8,70) for 35 ml of 
collection to reduce unspecific binding. After collection, until the total volume was 
collected, saliva was stored at +4 j.  
For purification, 100 ml and 300 ml of saliva were centrifuged (16’0007 k, 30 min, Sorvall 
Lynx 4000, Thermo Scientific, Madison, USA) for removing extraneous material. Then, 
saliva was diluted with Binding buffer (0,1 M TRIS and 0,2 M, pH 8,70) up to 0,7 liter and 
1,5 liter, respectively. p-Aminomethylbenzenesulfonamide–Agarose (Sigma) for the affinity 
chromatography matrix were added 3 ml and 6 ml, respectively, and both were left on 
magnetic stirrer +4°C/ON. 
Purification of salivary CA VI 
The affinity chromatography matrix was collected with Milli-Pore filtration system (Millipore 
Corporation, Burlington, USA) with vacuum, followed by washing with 500 ml (100 ml75 
times) and 1000 ml (100 ml710 times) of wash 1 buffer (0,1 M TRIS, 0,2 M Na2SO4, 0,2 M 
Benzamidine, 20% glycerol, pH 8,70), respectively. The following wash on each purification 
was carried out with 300 ml of the same buffer but at lower pH (7,00). The matrix was 
collected from the filtration system by pipetting into the chromatography column. Finally, 
CA VI was eluted in 2 ml fractions with the elution buffer (0,1 M TRIS, 0,4 M NaN3, 1mM 
Benzamidine, 20% glycerol, pH 7,0). For maximizing the amount of CA VI in the first 
fraction, the first volume of the elution buffer was pipetted into the column, removed to an 
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external centrifuge tube and left on a 3D-stirrer for 30 minutes. After incubation, CA VI was 
eluted, and fractions of 2 ml were collected. Fractions were analyzed using SDS-PAGE-
electrophoresis. The molecular weight of salivary CA VI was determined using Precision 
Plus ProteinTM Standards Dual Color (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and 
molecular weight marker and salivary CA VI bands were visualized using the Colloidal Blue 
Staining KitTM (Invitrogen). This purification protocol was repeated once, because after the 
first purification the amount of impurities observed in the SDS-PAGE gel was significant 
considering the further analysis of the protein. Concentration was measured using 
NanoDrop One (Thermo Scientific, Madison, USA).  
Milk CA VI 
500 ml and 1000 ml of human milk were donated by Tampere university hospital. After 
melting into liquid form, the milk samples were centrifuged (16’0007 k, 30 min, Sorvall Lynx 
4000, Thermo Scientific, Madison, USA). The solid, fatty layer was removed manually, and 
300 ml and 750 ml of milk were diluted with the binding buffer to the total volume of 1 liter 
and 1,75 liter, respectively. 4 ml and 12 ml of p-Aminomethylbenzenesulfonamide–Agarose 
(Sigma) was added for each of the dilutions. For reducing the unspecific binding, 25 ml 
and 75 ml of the collecting buffer were added to the diluted milk samples, respectively. 
Both of the diluted samples were left on magnetic stirrer +4°C/ON.  
Purification of milk CA VI 
The same protocol was followed as in salivary CA VI purification. 1 liter and 3 liters of wash 
1 buffer were used, following 250 ml and 1000 ml of wash 2 buffer used, respectively. The 
matrix was collected, and the first fraction was incubated and eluted as described earlier. 
All fractions were analyzed with SDS-PAGE electrophoresis. As well as for salivary CA VI, 
also the molecular weight of milk CA VI was determined using Precision Plus ProteinTM 
Standards Dual Color (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and molecular 
weight marker and milk CA VI bands were visualized using the Colloidal Blue Staining KitTM 
(Invitrogen). Like salivary CA VI, also milk CA VI was found to possess significant amount 
of impurities. Thus, milk CA VI fractions were also repurified to reduce the amount of 
impurities. Concentration was measured using NanoDrop One (Thermo Scientific, 
Madison, USA).  
 
Sample preparation 
Before further analysis, milk and salivary CA VI-samples were analyzed with SDS-PAGE to 
observe them in parallel manner. The molecular weight of milk and salivary CA VI was 
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determined using Precision Plus ProteinTM Standards Dual Color (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA) and molecular weight marker, milk and salivary CA VI bands were 
visualized using the Colloidal Blue Staining KitTM (Invitrogen). After reaching a sufficient 
level of purity and measuring the concentration, the elution buffer in both milk CA VI and 
salivary CA VI were changed to suitable buffers, 150 mM NaCl and 50 mM TRIS for high-
performance liquid chromatography, and 100mM ammonium acetate for mass 
spectrometry, respectively. The elution buffer was changed because of the relatively high 
concentration of NaN3 with Vivaspin Turbo 15 (30 mm7118 mm, Sartorius AG, Göttingen, 
Germany) resulting in NaN3-concentration being less than 10-9M to minimize its light 
absorbing characteristics on the light scattering analysis. After changing the buffer, the 
concentration was measured using NanoDrop One (Thermo Scientific, Madison, USA).  
 
High-performance liquid chromatography and dynamic light scattering 
experiments 
The molecular weight of CA VI was determined with high-performance liquid 
chromatography (HPLC) Shimadzu system (CBM-20A, Shimadzu Corporation, Kyoto, 
Japan) with Malvern Zetasizer GV instrument (Malvern Instruments Ltd., Worcestershire, 
UK) by using static light scattering (SLS) and dynamic light scattering (DLS) methods. 
HPLC system was equipped with solvent delivery unit LC-10Ai, degassing unit DGU-
20A5R, autosampler SIL-20A, and fluorescence detection RF-20Axs, UV/VIS detector SPD-
20A and communications bus module CBM-20A and was used for analyzing both CA VI 
samples. The separation was carried out using a Superdex 200 5/150 GL column (10 
mm7300 ml, particle size 13Gm, GE Healthcare, Uppsala, Sweden) and was equilibrated 
with filtered 50 mM TRIS, 150 mM NaCl, pH 7,50 running buffer. The chromatographic runs 
were performed in the thermostatic cabin and detector and column temperature were set 
to +12°C  with a flow rate of 0,1 lmlVW.  The sample volume was calculated so that 50 Gg of 
both of the CA VI proteins and 30 Gg of standard proteins were injected by using an 
autoinjector. In both runs, the detector and column temperature were Data were processed 
using Lab Solution version 5.51 (Shimadzu Co., Kyoto, Japan) and OmniSec 4.7 (Malvern 
Instruments Ltd., Worcestershire, UK) softwares. Molecular weight determination was 
performed two ways; (1) by calibrating the light scattering detector using the monomeric 
peak of bovine serum albumin and light scattering intensity and (2) by the size-exclusion 
chromatography standard curves of four standard proteins (Sigma-Aldrich, Inc., Saint 
Louis, MO, USA); bovine serum albumin 66,7 kD, alcohol dehydrogenase 150 kD, beta-
amylase 200 kD and carbonic anhydrase II 29 kD.  
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Batch-dynamic light scattering  
To verify the in-line DLS measurement, an individual measurement for determining the 
hydrodynamic diameter of milk and salivary CA VI, 0,9 lnlm  and 0,97 lnlm , respectively, was 
performed with batch-DLS-analysis using Malvern Zetasizer Nano (Malvern Instruments 
Ltd., Worcestershire, UK) equipped with 4mW laser lamp (o=633 nm). 100 Gl of both 
samples were analyzed, and five parallel measurements were calculated at the 
temperature of +25 °C. Data were processed using Zetasizer 7.03 software (Malvern 
Instruments Ltd., Worcestershire, UK). Average values of hydrodynamic diameter, d.nm, 
were computed by five individual measurements for both samples.  
Furthermore, the hydrodynamic diameter of salivary CA VI was analyzed in increasing 
temperature. First, sample was centrifuged (13’0007 k, 5 min) filtered with 0,2 Gm filter and 
diluted into lower concentration of 0,28 lnlm . Subsequent protocol was used: first, sample 
was equilibrated in each temperature for 10 minutes. Then, five parallel measurements 
were performed on each desired temperature; +20 °C, +25 °C, +30 °C, +37 °C, +40 °C, 
+45 °C, +50 °C, +55 °C, +60 °C, +65 °C and +70 °C.  This experiment was conducted for 
assessing the changes in hydrodynamic diameter as temperature is altered and determine 
the temperature range for the melting point of CA VI.  
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Results 
To date, the parameter defining the specific UV sensitivity as a concentration derivative, 
dA/dC, has not been reported in the literature. Thus, dA/dC for CA VI was computed using 
Protparam tool (Gasteiger et al., 2005). Carbonic anhydrase VI (CAH6_HUMAN; protein ID: 
P23280) protein sequence was selectively used from position 18 to position 308 to model 
native CA VI properties. Based on the chosen sequence resembling the intact protein 
without the signal peptide sequence (1-17 aa), dA/dC was calculated and further used in 
the computations of HPLC software OmniSec 4.7 (Malvern Instruments Ltd., 
Worcestershire, UK). Additionally, the theoretical value of CA VI isoenzyme’s molecular 
weight was retrieved from ProtParam tool to provide a theoretical reference value for SLS-
measured molecular weights by OmniSec 4.7.  
Table 1 Computed values for CA VI by ProtParam tool. 
Computed data by ProtParam tool 
Theoretical MW 33,56952 kD 
dA/dC 1,666 ml/g 
 
Purification of CA VI 
Both salivary and milk CA VI were purified twice due to significant impurities present after 
the first purification. Approximately 1l of human milk resulted in 1,630 lnlm  of CA VI. For 
salivary CA VI, the total of 400 ml of saliva resulted in 2 lnlm  of CA VI. Milk and salivary CAVI 
were analyzed in parallel with 10% SDS-PAGE gel. In picture 1 below, 11 µg of milk CA VI 
and 10 µg of salivary CA VI are presented. The purified milk CA VI showed a single, strong 
band close to the anticipated size, approximately 42 kD, in SDS-PAGE-gel among a small 
number of weaker bands both larger and smaller in size. Salivary CA VI showed a wider 
band around 42-36 kD.  
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Picture 1 The SDS-PAGE of native human milk and salivary CA VI. Left: molecular weight standards presented as 
kilodaltons (kD). Middle: purified native human milk CA VI Right: purified native salivary CA VI.  For both CA VI-proteins, 
molecular mass calculated from mobility resulting in approximately 42 kD.  
High-performance liquid chromatography and dynamic light scattering 
The molecular size of milk and salivary CA VI were estimated after liquid chromatography 
by SLS and DLS, respectively. The results are presented individually in the following 
subchapters.  
HPLC-DLS-analysis of milk CA VI  
HPLC-analysis resulted in approximate estimation of molecular weight of the milk CA VI 
isoenzyme. Also, the hydrophobic radius of milk CA VI was measured using DLS, both in-
line and batch, respectively. Data retrieved from the static light scattering (SLS), the 
standardized molecular weight and the direct light scattering (DLS) are presented in table 
2, along with the provided theoretical value for the molecular weight of CA VI. 
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Table 2 HPLC-DLS results of milk human CA VI. In the first section, theoretical molecular weight for the monomeric human 
CA VI (hCA VI) protein is provided by ProtParam. In the middle section SLS and in-line DLS results, molecular weight 
calculated by SLS, standardized molecular weight and hydrodynamic radius, are shown for peak 1-3 in the given retention 
volumes. In the last section, batch DLS-measurement for hydrodynamic diameter is shown.  
Sample Theoretical MW 
(kD) !!
SEC ret. volume 
(ml) 
SLS MW 
(kD) 
Stand. MW 
(kD) 
Rh DLS in-line 
(nm) 
Batch DLS 
(d.nm) 
milk hCA VI 33,56952 Peak 1 1,318 1642,000 414,686 N/A 15,25 
 
!! Peak 2 1,474 427,265 250,094 N/A !!!
!! Peak 3 1,562 203,815 188,025 217,21 !!
 
Graph 1 shows UV absorbance (A280), light scattering (RALS) and logarithmic value of 
molecular weight (log MW) as a function of retention volume (ml) for milk CA VI. The main 
peak of milk CA VI, marked as peak 3, was eluted in 1,56 ml retention volume according to 
UV absorbance A280, shown as a black curve in graph 1. However, SLS intensity peak 
differed from its shape when compared with UV absorbance in milk CA VI as it is depicted 
in light grey. SLS intensity for the main peak predicted a molecular weight of 203,815 kD 
for milk CA VI, which is depicted as a near-horizontal dark grey line across the peak 3. 
There are also other molecular weight estimates shown in the graph; at retention volume 
Vret,1=1,318 ml, the molecular weight estimate is approximately 1642 kD, and Vret,2=1,474 
ml the molecular weight of the particles is estimated to be 427 kD. 
In-line DLS data for the eluted peak was also collected, but due to its significantly high 
values and standard deviation, the average of the hydrodynamic radius being 217,21 nm 
and standard deviation 39,79 (data not shown), it is not shown in the graph.  
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Graph 1 Assessment of the oligomeric size of milk human CA VI. Size-exclusion chromatography was used to study the 
properties of human native, milk CA VI. The X-axis shows the retention volume for the analyzed sample. The left Y-axis 
shows the UV absorption intensity of 280 nm wavelength (A280, black curve) and Right Angle Light Scattering intensity 
(RALS, light grey). In the right Y-axis, logarithmic values for molecular weight were computed by light scattering intensity. 
In-line DLS-measurement for hydrodynamic radius Rh is not shown.  
As the hydrodynamic radius was unsuccessfully determined with in-line DLS, the 
hydrodynamic diameter, d.nm, was additionally studied with batch DLS. Five parallel 
measurements resulted on the average of 15,25 nm for d.nm of milk CA VI. Graph 2 shows 
the five, parallel measurements as a size distribution by the sample’s volume. PDI for the 
milk isoenzyme sample was recorded to be 0,736.  
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Graph 2 Size distribution by volume for five parallel measurements of milk CA VI. Records 7-11 show the five individual 
measurements of d.nm of the milk CA VI. Record 12 shows the average distribution based on the records 7-11.  
HPLC-DLS-analysis of salivary CA VI 
Like milk CA VI, also salivary CA VI was analyzed using size-exclusion chromatography 
and light scattering. Data in the table 3 presents SLS measurement of molecular weight 
(kD) for three distinct peaks 1-3 in the given retention volume (ml) and standardized 
molecular mass. In addition, it shows the hydrodynamic radius and hydrodynamic diameter 
measured by in-line DLS and batch-DLS, respectively.  
Table 3 HPLC-DLS results of salivary CA VI. In the first section, theoretical molecular weight for the monomeric human 
CA VI (hCA VI) protein is provided by ProtParam. In the middle section SLS and in-line DLS results, molecular weight 
calculated by SLS, standardized molecular weight and hydrodynamic radius, are shown for peak 1-3 in the given retention 
volumes. In the last section, batch DLS-measurement for hydrodynamic diameter is shown.  
 
Sample Theoretical MW (kD)   
SEC ret. volume 
(ml) 
SLS MW 
(kD) 
Stand. MW 
(kD) 
Rh DLS in-line 
(nm) 
Batch DLS 
(d.nm) 
salivary hCA VI 33,56952 Peak 1 1,306 2756,000 431,135 N/A 17,08 
   Peak 2 1,426 675,188 292,198 N/A  
!   Peak 3 1,562 204,509 188,025 11,43  
 
Graph 3 shows UV absorbance (A280), light scattering (RALS) and logarithmic value of 
molecular weight (log MW), as a function of retention volume (ml) for salivary CA VI. The 
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main peak, peak 3 depicted as a black curve, elutes in 1,56 ml retention volume. In 
retention volume 1,2 ml, a strong light scattering peak is shown as light grey as it is seen 
also in retention volume 1,56 ml but in lower intensity. Based on SLS measurements, 
molecular weight for the particles in peak 3 was computed to be 204,509 kD as it can be 
seen plotted as a dark grey line across the peak 3. For peak 1 and 2, the computed 
molecular weights were 2756 kD and 675,188 kD, respectively. Standardized molecular 
weight for peak 3 was 188,025 kD, whereas for peaks 1 and 2 the values were 431,135 kD 
and 292,198 kD, respectively.  
Particle size was measured with in-line DLS and batch DLS. As seen in the graph 3, eluted 
peak 3 indicated the hydrodynamic radius to be 11,43 nm measured with in-line DLS.  
 
Graph 3 Assessment of the oligomeric size of salivary human CA VI. Size-exclusion chromatography was used to study 
the properties of human native, salivary CA VI. In the X-axis, the retention volume for the analyzed sample is shown. The 
left Y-axis presents the UV absorption intensity of 280 nm wavelength (A280, black curve) and Right Angle Light 
Scattering intensity (RALS, light grey). In the right Y-axis, logarithmic values for molecular weight were computed by light 
scattering intensity. In-line DLS-measurement for hydrodynamic radius Rh is presented as a scatter plot also shown in 
the Y-axis.  
The hydrodynamic diameter was also studied with batch DLS. Results are seen in graph 5, 
where the individual measurements for determining the hydrodynamic diameter are seen. 
Five parallel measurements resulted in average d.nm of 17,08 nm for salivary CA VI 
isoenzyme. PDI for the given salivary CA VI sample was recorded to be 0,481. 
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Graph 4 Size distribution by volume for five parallel measurements of milk CA VI. Records 1-5 show the five individual 
measurements of the salivary CA VI.  
Batch DLS 
The hydrodynamic diameter of salivary CA VI isoenzyme was estimated with DLS analysis. 
Table 4 shows the average d.nm, standard deviation for d.nm, the average percentage of 
the studied peak area, average PDI and standard deviation for PDI, for each of the five 
parallel measurements in each temperature, respectively.  
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Table 4 The measured values of batch-DLS-analysis. Salivary CA VI was used for determining the melting point for the 
studied protein. Five parallel measurements of hydrodynamic diameter were used to determine the average d.nm 
(average d.nm CA VI peak), the average proportional area of the studied peak (Area Vol (%) CA VI peak) and average 
PDI. In addition, their standard deviations were calculated, respectively (STD d.nm and STD PDI).  
Temperature 
("#$ 
Average d.nm CA VI peak 
(nm) STD d.nm 
Average area Vol. CA VI peak 
(%) 
Average 
PDI 
Standard deviation 
PDI 
20 23,53 0,496960763 100 0,458 0,005612486 
25 21,58 0,66543219 100 0,487 0,061924955 
30 18,76 2,881773759 17,1 0,433 0,075400928 
37 21,05 0,998839326 100 0,479 0,020916501 
40 21,1 3,756776544 100 0,455 0,05157034 
45 19,03 2,78890301 100 0,431 0,065078414 
50 28,76 6,110864914 100 0,384 0,11361558 
55 129,6 27,77314926 88,6 0,213 0,004774935 
60 1456 682,5727009 0,3 0,514 0,059038123 
65 1470 91,903754 100 0,279 0,062617889 
70 1532 91,69896401 100 0,489 0,070604532 
 
In the graph 5, the average value of d.nm is presented as the temperature is steadily 
increased from +20 °C to +70°C.  
  
 
Graph 5 The hydrodynamic diameter of human salivary CA VI in given temperature points. The resulting average value 
for each measurement (n=5) is shown in the graph. X-axis shows the temperature in °C and Y-axis presents the 
hydrodynamic diameter in nm. 
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Throughout the data, a strong peak was detected at 19-22 nm for the hydrodynamic 
diameter. When reaching +50 °C, the hydrodynamic diameter changes into the micrometer 
scale, as seen the significant change in +50°C-+60°C range. A clear precipitation was also 
observed after removing the cuvette from the chamber. At the range of +25°C and +45°C, 
the average d.nm was 20,3 ± 1,3 nm, and the average polydispersity index 0,411 ± 0,094.  
Mass spectrometry 
Mass spectrometric studies were planned to perform in collaboration with Prof. Janne Jänis 
at the university of Eastern Finland. However, due to technical challenges, the complete 
mass spectrometry analyses with detailed experiments were postponed to the near future. 
Interestingly, the first results indicated certain differences in post-translational 
modifications of milk and salivary CA VI forms (Janne Jänis, personal communication, July 
6th, 2018). However, more detailed analysis of the mass spectrometric data is still 
underway. Even though preliminary results considering the milk and salivary CA VI 
glycosylations were retrieved, additional information about sample preparation or the given 
apparatus and used methods are lacking. Thus, these results cannot be presented or 
discussed as it would not be considered as a good scientific practice.  
 
Discussion 
All the experiments and their results are critically discussed in the following subchapters, 
respectively. First, the SDS-PAGE analysis of milk and salivary CA VI are discussed in terms 
of molecular weight. Secondly, HPLC-DLS results are discussed considering the measured 
molecular weight in physiological conditions and the particle size of milk and salivary CA 
VI. Finally, batch DLS results, considering the size determination of salivary CA VI as well 
as studying the melting point of salivary CA VI, are discussed.  
SDS-PAGE-analysis 
After the second purification, the salivary CA VI band remained blurry, even though it was 
significantly purified in comparison with the first result. This tendency of salivary CA VI can 
be seen in the picture 1, as the salivary CAVI-band is not as well-defined and sharp as it 
was in milk CA VI. Milk CA VI-band possesses a sharper and stricter appearance 
suggesting to a less extensive deglycosylation than in salivary CA VI. Band for salivary CA 
VI shares this characteristic appearance with the previously reported publications of 
salivary CA VI in Western blot -analysis (Murakami and W S Sly, 1987; Karhumaa et al., 
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2001; Leinonen et al., 2001; Kimoto et al., 2006). The major band is seen at the 42 kD, and 
the weaker band at 36 kD represents the deglycosylated form of salivary CA VI (Karhumaa 
et al., 2001). The deglycosylated molecular weight was previously demonstrated as both 
CA VI proteins were digested with PNGase F and then, the molecular weights were shown 
to be identical (Karhumaa et al., 2001). For milk CA VI, deglycosylations are thought to be 
fewer as mentioned and thus, protein is seen solely at 42 kD as presented in figure 1.  
Based on the previous experiences of our research group, the affinity chromatography can 
yield mg quantities of carbonic anhydrase per one liter of either saliva or milk. Considering 
that both of the CA VI isoenzymes used in the study were native and not recombinantly 
produced, the amount of impurities was successfully reduced. Still, it has to be accounted 
that as long as some impurities exist within the studied protein, there are contaminants 
present that might affect the subsequent analysis.  
Since the research is continued using mass spectrometry, it will be interesting to see 
whether the glycosylations differ. As the proteins are translated from the same gene these 
would be attributable to variations in post-translational modifications. If the glycosylation is 
reasonably consistent, it should theoretically produce a coherent and sharp band on SDS-
PAGE gel. This raises the question whether the glycosylations in salivary CA VI are less 
stable than in milk CA VI. However, it has to be noted that oligosaccharides don’t respond 
to the electric current like proteins and thus, glycoproteins are usually seen as more 
diffused in SDS-PAGE (Seppo Parkkila, personal communication, July 2nd, 2018). Since 
they do not assemble perfectly into spheroid form and might possess charged areas within 
the molecule, they appear as a blur on the gel. This makes it challenging to argue the 
absolute glycosylation differences between milk and salivary CA VI isoenzymes. As this 
research is continued, it would be suggested analyzing milk and salivary CA VI with a 
looser gel, e.g. 8%, so that resolution would improve, and sharper bands would be seen. 
Also, the mass spectrometric identification would be desirable to perform. To conclude, 
these analyses would offer additional information about milk and salivary CA VI post-
translational structures.  
HPLC-DLS 
Both milk and salivary CA VI eluted in the same volume, 1,56 ml, suggesting to the similar 
shape and size in overall structure. In both cases, the large RALS peak (graph 1 and 3, 
grey curve) eluting before the main peak at 1,1 ml indicates high scattering intensity that is 
due to presence of aggregating protein. However, as the UV absorbance (graph 1 and 3, 
black curve) of the protein shows, this is assumed for only a minor percentage of the 
sample.  
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Molecular weight was determined to be nearly identical by BSA calibration; milk CA VI 
estimated to be 203,815 kD and salivary CA VI 204,509 kD. As their sizes were calculated 
by protein standard, the same retention volume resulted the same size estimation of 
188,025 kD for both proteins. This estimate being slightly smaller than the SLS 
approximation would possibly result from the proteins’ oligomeric assembly or interactions 
with the column matrix that would ultimately affect its penetration due to irregular shape. 
As the monomeric CA VI has a molecular weight of 42 kD, the HPLC measurements hint to 
oligomeric assembly for the CA VI. To assess the size more carefully, particle size was 
measured with both in-line and batch DLS. As the graphs 1 and 3 depict, the eluting peak 
3 for both samples measured the salivary hydrodynamic radius to be 11,43 nm with in-line 
DLS but for the hydrodynamic radius of milk CA VI, reliable results were not collected (STD 
39,79). For batch DLS however, hydrodynamic diameter for milk CA VI was measured to 
be 15,25 nm and for salivary CA VI 17,08 nm. However, the PDI for the milk CA VI was high, 
0,736, implying to great polydispersity within the sample. For salivary CA VI, PDI of 0,481 
implies a moderately broad polydispersity of the sample. Since high polydispersity 
indicates values being further apart from each other, the salivary CA VI measurement offers 
a more reliable result for CA VI hydrodynamic diameter as it has a lower PDI compared to 
milk CA VI.   
As the molecular weight can be estimated by Calculator-tool in Zetasizer 7.03-software, the 
computed molecular weight for the hydrodynamic diameter of 17,08 nm is 508,9 kD for a 
globular protein. Since the additional, adsorbed structures on the surface and non-
spherical form are known to affect the measured hydrodynamic diameter (Shaw, 2018), it 
has to be emphasized that the measured hydrodynamic diameter for CA VI, that is 
potentially non-spheroid and has glycosylations within its structure, might appear 
considerably larger in comparison with the absolute core of the protein. Thus, it has to be 
noted that this DLS-based value is generalized estimation made in silico and is not 
considered as relevant as the molecular weight measured with SLS as the result can be 
affected by the irregular shape of the oligomer. However, it has to be noted that apparently 
larger particle size is somewhat desired result considering that CA VI is thought to be non-
spherical and has protruding surface structures.  
Based on the molecular weight estimations and the large hydrodynamic radius, there is 
rather strong evidence to argue that human CA VI assembles into a pentameric state in a 
physiological buffer. To date, the pentameric structure has not been reported. The 
pentameric result is still plausible with the SDS-PAGE-result. Due to the extreme conditions 
in SDS-PAGE sample preparation, CA VI is reduced into a monomeric state because of the 
high temperature and the presence of mercaptoethanol in the loading buffer. Generally, 
only the monomeric band is seen in the SDS-PAGE-gel.  
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Despite the several attempts, the complete and native CA VI has not been managed to 
crystallize successfully. To date, only the catalytic domain of human CA VI, including amino 
acids 32-279, was crystallized (Pilka et al., 2012). It was reported that amino acids 21-31 
were disordered and, thus, excluded from the computed, structural model (Pilka et al., 
2012). Dimeric tendency for recombinantly produced human CA VI was reported as SEC 
analysis showed a two-peaked profile of CA VI suggesting to a presence of a dimeric CA 
VI as well as monomeric CA VI (Pilka et al., 2012). The published SEC-graph by Pilka et al. 
has somewhat altered characteristics than the graphs 1 and 3 showing three peaks of 
which the peak 3 is the largest by its area. Pilka et al. show a graph with the nearly equal 
peaks of which the other is estimated to have the same molecular weight than ‘molecular 
standard’ 66 kD. Pilka et al. provided no additional data to support the dimeric nature as 
SEC was eventually used for protein purification in the described study. Still, Pilka et al. 
used recombinantly produced CA VI that differs from the native CA VI as it lacks amino 
acids from both N- and C-termini. In the given study, salivary and milk CA VI were native 
proteins and thus, these results cannot be compared as the studied structure is different. 
In conclusion, the suggested pentameric assembly that was discovered provides new 
information about native CA VI protein assembly. Also, the diffraction data of full-length CA 
VI would offer essential information considering the complete structure of CA VI and 
describe the oligomerization sites of CA VI as well. 
The dimeric tendency of sheep lacrimal CA VI was briefly reported based on Western 
analysis (Ogawa et al., 2002). Yet, no additional experiments to support the finding were 
shown.  
As pentameric CA VI has not been reported previously, this novel assembly proposes new 
aspects considering the functionality of CA VI. Pentameric structure for CA VI has been 
discovered in CA VI found in zebra fish since it is found to form a complex with the pentraxin 
domain and subsequently form a pentamer of those complexes (Patrikainen et al., 2017). 
As it is highly expressed in tissues forming the physical barrier against external 
environment, e.g. gut, skin and gills, it was thought to be a component of the innate immune 
system (Patrikainen et al., 2017). Human CA VI differs from CA VI-PTX-complex as it seems 
to form a pentameric structure solely. Thus, the functional meaning of this assembly is 
currently unclear. Interestingly, the pentameric assembly was retained in human body 
temperature, +37 °C, indicating that CA VI is able to sustain its form in physiological 
conditions as well as in body temperature. As the research is continued, the monomeric 
CA VI could be studied by its structure in silico to evaluate potential oligomerization sites. 
It would potentially explain how the given pentamer is formed. Also, the pentameric 
assembly could be verified by performing the same analyses with recombinantly produced 
protein.  
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HPLC-DLS-analysis provided the desired data considering the molecular weight and 
hydrodynamic size of milk and salivary CA VI isoenzymes. For sample preparation, it would 
have been appropriate to follow a more detailed protocol in order to minimize measuring 
errors. The concentration values of protein samples were not adjusted for the specific value 
of CA VI extinction factor resulting in slightly greater values and thus, the absolute amount 
of protein injected in the HPLC-DLS-analysis was slightly less than 50 Gg in both samples. 
This might partially explain the unsuccessful in-line DLS-measurement for milk CA VI, as 
there might have been an insufficient number of CA VI isoenzyme particles for determining 
the hydrodynamic radius. Also, the injected samples were not thoroughly centrifuged after 
collecting the samples from concentrating tubes but briefly spinned before transferring into 
HPLC-autosampler vials. Also, samples were not filtered with 0,2 Gm filter. This might have 
caused the presence of the aggregating protein as seen in the graphs 1 and 3 as a high 
peak of RALS (grey curve) in ~1,1 ml retention volume. To avoid this, filtering would be 
advised to perform or alternatively the sample could be thoroughly centrifuged and 
transferred into a new tube. Due to the complex shape of the UV-absorbance curve in 
graphs 1 and 3, all the eluted proteins of different peaks could additionally be fractioned 
and subsequently analyzed with SDS-PAGE to reassure their molecular weight.  
For good scientific practice, it would be appropriate to repeat the complete analysis with a 
more detailed sample preparation described previously to verify the measured values as 
the given experiment was performed only once for each sample. In addition, it would be 
intriguing to analyze both salivary and milk CA VI in SEC with different temperatures to 
observe how the temperature would affect its oligomeric assembly. 
Batch DLS 
Salivary CA VI was more carefully studied as the result for hydrodynamic diameter was 
verified in a separate measurement. As seen in the graph 3, average d.nm for salivary CA 
VI between 25-45 °C is 20,304 ± 1,3 nm. Scattering intensity and d.nm remain constant as 
shown in the table 4. Similarly, PDI was considered stable between 25-45 °C, average PDI 
being 0,457±1,325. However, the percentage of the studied peak area was 100% in all the 
measured temperatures except +30°C, +55 °C and +60 °C (17,1%, 88,6% and 0,3% 
respectively) showing that majority of the measurements recorded the hydrodynamic 
radius of CA VI accurately since the resulting diameter was highly similar in comparison 
with the hydrodynamic radius measured with SLS. Since there are no previous reported 
values for the hydrodynamic size of CA VI, this result cannot be compared to the 
preexisting data.  
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The measured hydrodynamic diameter for salivary CA VI was drastically increased at +55 
°C indicating the presence of denatured CA VI aggregates, hence, the melting point for 
salivary CA VI must reside between +50 - +55 °C. This result supports the formerly 
measured value, +53,6 °C (Kazokaite et al., 2015), for the melting temperature of native, 
salivary CA VI isoenzyme.  
Since both of the studied CA VI isoenzymes are native proteins, the impurities will affect 
adversely by increasing the polydispersity of the analyzed samples. As the percentage of 
the peak area in +30°C was only 17%, it would be advisable to re-determine the given 
value for large contaminants. Thus, to lower the polydispersity index of the samples, the 
amount of impurities should be reduced even further. Also, significantly differing values 
could be excluded from the data for lowering the PDI. 
 Due to insufficient amount of milk CA VI, the batch DLS for the given isoenzyme was not 
performed in this study. For the upcoming experiments, similar batch DLS analysis for milk 
CA VI would provide reassuring data for the melting point of salivary CA VI. It would also 
confirm that both milk and salivary CA VI would possess the same melting temperature, or, 
whether the glycosylation differences would have an effect on the given parameter. For 
recombinantly produced CA VI, both in E. Coli and in mammalian cells, the melting 
temperature was shown to be slightly lower than for native, salivary CA VI (Kazokaite et al., 
2015). This was assumed to depend on glycosylation differences (Kazokaite et al., 2015). 
Hence, it would be recommended to analyze milk and salivary CA VI isoenzymes in parallel 
manner as this study is continued in the near future. 
Conclusion 
To conclude this study, milk and salivary CA VI were purified with affinity chromatography, 
and SDS-PAGE analysis was parallelly performed to assess their molecular weight and 
glycosylation differences. In SDS-PAGE analysis salivary CA VI was seen as more 
dispersed than milk CA VI, suggesting less extensive deglycosylation in milk CA VI. This 
variation between the milk and salivary CA VI could be more properly studied with MS 
identification. 
The molecular weight and particle size were estimated with HPLC-DLS and batch DLS, 
respectively. SLS determined the milk CA VI to have a molecular weight of 203,815 kD and 
204,509 kD for salivary CA VI. Standardized molecular weight for both milk and salivary CA 
VI was calculated to be 188,025 kD. The hydrodynamic radius for milk CA VI was not 
retrieved from in-line DLS, but from batch DLS, the hydrodynamic diameter was measured 
to be 15,25 nm. For salivary CA VI, the hydrodynamic radius from in-line DLS was measured 
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to be 11,43 nm and batch DLS measured the hydrodynamic diameter to be 17,08 nm. The 
hydrodynamic diameter of salivary CA VI was additionally determined with increasing 
temperature and found to have an average of 20,3 ± 1,3 nm between temperatures +25°C 
and +45°C. The great particle size and molecular weight indicate that CA VI assembles as 
an oligomer, a pentameric structure being the most probable form. To date, this pentameric 
structure has not been reported. This novel form offers new insights for CA VI functions that 
need to be further studied. Lastly, the range for melting point of the salivary CA VI was 
measured to be +50 - +55 °C. The result was consistent with the previously reported value. 
MS analyses are underway to determine potential differences in post-translational 
modifications, such as glycosylation, in both milk and salivary CA VI enzymes.   
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Appendices 
Appendix 1 Used solutions in protein purification 
Solution Reagents pH 
Collecting buffer for CA VI 0,1 M TRIS (VWR 0497, #040GC459) 
0,2 M Na2SO4 (Honeywell, #BCBS8593V) 
0,2 M Benzamidine (Sigma B6506, #117K0123) 
8,70 
Binding buffer for CA VI 0,1 M TRIS (VWR 0497, #040GC459) 
0,2 M Na2SO4 (Honeywell, #BCBS8593V) 
8,70 
Wash 1 buffer for CA VI 0,1 M TRIS (VWR 0497, #040GC459) 
0,2 M Na2SO4 (Honeywell, #BCBS8593V) 
0,2 M Benzamidine (Sigma B6506, #117K0123) 
20% glycerol (Sigma, #SHBH4364V) 
8,70 
Wash 2 buffer for CA VI 0,1 M TRIS (VWR 0497, #040GC459) 
0,2 M Na2SO4 (Honeywell, #BCBS8593V) 
0,2 M Benzamidine (Sigma B6506, #117K0123) 
20% glycerol (Sigma, #SHBH4364V) 
7,00 
Elution buffer for CA VI 0,1 M TRIS (VWR 0497, #040GC459) 
0,4 M NaN3 (VALMISTAJA) 
1mM Benzamidine (Sigma B6506, #117K0123) 
20% glycerol (Sigma, #SHBH4364V) 
7,0 
HPLC buffer 150 mM NaCl (VWR, #17L184138)  
50 mM TRIS (VWR 0497, #040GC459) 
7,5 
MS buffer 100 mM ammonium acetate (Fluka, #BCBJ9119V)  NA 
 
